Media Coverage

VetDC commercializes canine lymphoma drug

Apr 11, 2017 - Animal Pharm

By Sian Lazell
Animal Pharm
April 11, 2017

Pet cancer therapy specialist VetDC has made its Tanovea-CA1 treatment for canine lymphoma commercially available in the US.

Tanovea-CA1 (rabacfosadine injection) can now be purchased by licensed veterinarians in the US. The treatment was conditionally approved by the US FDA's Center for Veterinary Medicine (CVM) in January, pending a full demonstration of effectiveness.

VetDC president and chief executive Steven Roy told Animal Pharm the firm is distributing and selling Tanovea-CA1 itself. 

The product is administered intravenously every three weeks for up to five doses. It is the first and only new animal drug indicated for the treatment of lymphoma in dogs.

The treatment is a small molecule drug designed to preferentially target and attack rapidly dividing cancer cells involved in lymphoma. Colorado-based VetDC said Tanovea-CA1 has demonstrated anti-tumor activity in both naïve and relapsed canine lymphoma cases, with a generally well-tolerated safety profile.

Dr Craig Clifford, a board-certified veterinary oncologist and clinical investigator at Hope Veterinary Specialists in Malvern, Pennsylvania, said: "Based on our first-hand experience as part of a robust clinical trials program, we believe Tanovea-CA1 has the potential to become a cornerstone for the treatment of lymphoma in dogs." 

Dr Terry Opgenorth, co-founder of VetDC, commented: "VetDC stands out among an elite group of pure-play animal health start-ups that have advanced a novel program from development through commercialization. We believe Tanovea-CA1 represents a significant breakthrough in the rapidly evolving field of veterinary oncology."

Many other US firms are also focused on treatments in the pet oncology space. These include: HylaPharm, a start-up working on a targeted, injectable treatment for a range of cancers in dogs; Kansas-based Aratana, which markets Blontress (canine lymphoma monoclonal antibody B-cell) and Tactress (canine lymphoma monoclonal antibody T-cell); and Anivive Lifesciences, which is developing a treatment for solid tumors in dogs.

Swedish company Oasmia Pharmaceutical also recently decided to move its veterinary oncology division to the US, the most developed market for pet cancer treatments.

Reprinted with permission of Animal Pharm News




News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum